Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian Cancer

Withdrawn before enrolling · Phase 1/Phase 2

Conditions studied: Ovarian Cancer

In brief

RATIONALE: Drugs used in chemotherapy, such as doxorubicin and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving doxorubicin together with carboplatin may kill more tumor cells. PURPOSE: This phase I and phase II trial is studying the side effects and best dose of carboplatin when given together with doxorubicin to see how well it works in treating patients with recurrent ovarian cancer.

Key facts

Study ID

NCT00562185

Run by

University of Texas Southwestern Medical Center

People needed

0

Starts

2008-05-01

Expected to finish

2009-03-01

Last updated by the study team

2017-11-20

Who can join

Age: 18 and older, up to 120. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• GOG performance status 0, 1, or 2
• Life expectancy > 6 months
• Absolute neutrophil count ≥ 1,500/uL
• Platelet count ≥ 100,000/uL
• Hemoglobin > 9.0 g/dL
• Creatinine ≤ 2.0 mg/dL
• Bilirubin ≤ 1.5 x upper limit of normal (ULN)
• SGOT and alkaline phosphatase ≤ 3 x ULN
• Neuropathy (sensory and motor) ≤ CTCAE grade 1

You may not qualify if…

• GOG performance status 3 or 4
• Pregnant or breastfeeding
• History of hypersensitivity reactions attributed to a conventional formulation of doxorubicin hydrochloride or the components of DOXIL®
• Abnormal LVEF as determined by gated cardiac radionucleotide scan (MUGA)
• Septicemia or severe infection
• Acute hepatitis or severe gastrointestinal bleeding
• Any of the following:
• Unstable angina
• Myocardial infarction within the past 6 months
• NYHA class II-IV heart failure
• Uncontrolled angina
• Severe uncontrolled ventricular arrhythmias
• Clinically significant pericardial disease
• Electrocardiographic evidence of acute ischemic or active conduction system abnormalities
• Patients with evidence of abnormal cardiac conduction (e.g., bundle branch block or heart block) are eligible if their disease has been stable for the past six months
• Other invasive malignancies within the past 5 years except for nonmelanoma skin cancer
• PRIOR CONCURRENT THERAPY:
• Inclusion criteria:
• See Disease Characteristics
• At least 6 months since prior adjuvant regimen
• At least 4 weeks since prior salvage treatment
• May have received secondary cytoreduction for recurrent ovarian cancer
• May have received prior intraperitoneal therapy for ovarian cancer
• May have received no more than 2 prior platinum and taxane-based regimens
• May have received prior intraperitoneal platinum during front-line treatment

Where it is running

• Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.